Hepatitis B News and Research

Latest Hepatitis B News and Research

Hepatitis C common among HIV-positive patients in sub-Saharan Africa

A new study has found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV...

7 May 2015

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

A 12-week dose of an investigational three-drug hepatitis C combination cleared the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study in the May 5, 2015, issue of The Journal of the American Medical Association.

7 May 2015

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on the research of Dr Matteo Iannacone of the San Raffaele Scientific Institute in Milan where intravital microscopy is being applied to the study of host-viruses and associated immune responses.

7 May 2015

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV.

6 May 2015

New study finds high levels of HCV infection among HIV-infected people across Africa

A new study has found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV.

6 May 2015

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

5 May 2015

TDF switch effective in Asian chronic HBV patients

Switching therapy to tenofovir disoproxil fumarate is effective in treatment-resistant chronic hepatitis B, show results from a cohort of Asian patients.

29 Apr 2015

Kidney damage unlikely with TDF monotherapy in chronic HBV patients

In patients with chronic hepatitis B virus infection, treatment with tenofovir disoproxil fumarate does not significantly increase the risk of developing renal dysfunction compared with entecavir treatment, a US team reports.

29 Apr 2015

Patients with adefovir-resistant HBV benefit from TDF monotherapy

Tenofovir disoproxil fumarate alone elicits a response comparable to that of TDF plus entecavir in heavily pretreated patients with chronic hepatitis B virus infection resistant to adefovir dipivoxil, research suggests.

29 Apr 2015

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit.

29 Apr 2015

Will new hepatitis C treatments strain payers’ budgets? An interview with Dr Chhatwal

Our analysis shows that these drugs would not save overall healthcare money, but would add to the budget. When something is cost effective, it does not necessarily mean it is going to save money. It essentially implies that we're willing to spend additional money to gain additional benefits...

28 Apr 2015

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence.

27 Apr 2015

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

A new study revealed today at The International Liver Congress 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response at 4 weeks (SVR4) was observed in 98% of patients and in 95% at 12 weeks (SVR12).

27 Apr 2015

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

25 Apr 2015

Combination treatment effective for HCV genotype-1 mono-infected patients

Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations.

25 Apr 2015

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT).

25 Apr 2015

Systematic review shows hepatitis B and C testing lacking in many European countries

The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver Congress 2015.

25 Apr 2015

Occurrence of advanced liver fibrosis similar for patients with HCV infection

Study results presented today at The International Liver Congress 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.

25 Apr 2015

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Results presented today at The International Liver Congress 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.

25 Apr 2015

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).

25 Apr 2015

Hepatitis B News and Research

Latest Hepatitis B News and Research

Hepatitis C common among HIV-positive patients in sub-Saharan Africa

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

New study finds high levels of HCV infection among HIV-infected people across Africa

LaVision BioTec reports on the research work of the Milan-based Iannacone Laboratory to study virus responses using intravital microscopy

TDF switch effective in Asian chronic HBV patients

Kidney damage unlikely with TDF monotherapy in chronic HBV patients

Patients with adefovir-resistant HBV benefit from TDF monotherapy

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Will new hepatitis C treatments strain payers’ budgets? An interview with Dr Chhatwal

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Combination treatment effective for HCV genotype-1 mono-infected patients

New data supports use DAAs in patients with HCV recurrence following liver transplantation

Systematic review shows hepatitis B and C testing lacking in many European countries

Occurrence of advanced liver fibrosis similar for patients with HCV infection

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis B News and Research

Latest Hepatitis B News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in